4
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0001193125-26-017056
Co-Chief Executive Officer sold 138,188 shares at an average $13.59 ($1,877,570)
- Co-Chief Executive Officer acquired 200,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Klee Justin B. · Co-Chief Executive Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-15 | Exercise or conversion : show line 1 in the form | +197,153 | $7.57 | $1,492,448 | 3,514,739 | D |
| 2026-01-15 | Sale : show line 2 in the form | −136,193 | $13.58 | $1,849,869 | 3,378,546 | D |
| 2026-01-16 | Exercise or conversion : show line 3 in the form | +2,847 | $7.57 | $21,552 | 3,381,393 | D |
| 2026-01-16 | Sale : show line 4 in the form | −1,995 | $13.89 | $27,701 | 3,379,398 | D |
| Open-market sales · 138,188 sh · avg $13.59 · $1,877,570 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-01-15 | Exercise or conversion : show line 5 in the form Stock Option (Right to Buy) | −197,153 | 2,847 | D |
| 2026-01-16 | Exercise or conversion : show line 6 in the form Stock Option (Right to Buy) | −2,847 | 0 | D |
Loading xslF345X05/ownership.xml…